DAFTAR PUSTAKA

Ahmad, S. 2010. Pathogenesis, Immunology and Diagnosis of Latent Mycobacterium tuberculosis Infection. Clinical and Developmental Immunology. 2011 (1) : 1-17.

Aye, K.S., Nakajima, C., Yamaguchi, T., Win, M.M., Shwe, M.M., Win, A.A. (2016). Genotypic Characterization multi Drug Resistant Mycobacterium tuberculosis isolates in Myanmar. J Infect Chemother.

Ban˜uls, A,L., Sanou, A., Anh, N,T,V., Godreuil, S. 2015. Mycobacterium tuberculosis: Ecology and Evolution of A Human Bacterium. Journal of Medical Microbiology. 64 : 1261–1269.

Barru, M. 2020. Mutasi Gen Gyra dan Gyrb Pada Isolat Klinis *Mycobacterium tuberculosis* Resistan Ofloxacin di Sumatera Bagian Utara Indonesia. Universitas Sumatera Utara

Barry, V.C., Belton, J.G., Conalty, M.L., Denneny, J.M., Edward, D.W., O'Sullivan, J.F., Twomey, D., Winder, F, 1957, A New Series of Phenazines (Rimino- Compounds) with High Antituberculosis Activity, *Nature,***179**, 1013–1015.

Brennan dkk, 2008, Handbook of Anti-Tuberculosis Agents, *Global Alliance for TB. Drug Development*, **88** (2), 85-170.

Carolia N, Mardhiyah A, 2016. MultiDrug Resistant Tuberculosis pada Pasien Drop Out dan Tatalaksana OAT Lini Kedua. Jurnal Kedokteran Universitas Lampung:5(2):11-15

Centers for Diseases Control and Preventions (CDC). 2021. Core Curiculum on Tuberculosis: What the Clinician Should Know. https://www.cdc.gov/tb/education/corecurr/pdf/CoreCurriculumTB-508.pdf

Cohen, J., 2013, Approval of Novel TB Drug Celebrated—with Restraint, *Science*, **339,** 130. Cohen-Gonsaud, M., Ducasse, S., Hoh, F., Zerbib, D., Labesse, G. & Quemard, A., 2000, Crystal Structure of MabA from *Mycobacterium tuberculosi*

Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S.V., Eiglmeier, K., Gas, S., Barry, C. E., Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies,

R.,Devlin, K., Feltwell, T., Gentles, S., Hamlin, N., Holroyd, S., Hornsby, T., Jagels, K., Krogh, A., McLean, J., Moule, S., Murphy, L., Oliver, K., Osborne, J., Quail, M. A., Rajandream, M.- A., Rogers, J., Rutter, S., Seeger, K., Skelton, J., Squares, R., Squares, S., Sulston, J. E., Taylor, K., Whitehead, S., Barrell, B. G., 1998, Deciphering the Biology of *Mycobacterium tuberculosis* from The Complete Genome Sequence, *Nature*, **393**: 537–544.

Cordoba, B.C., Eusebio, D.M.J., Velasco, R.A., Salazar, R.M., Laborin, R.L., and Cuevas, R.Z., 2015. Mutation at embB Codon 306, a Potential Marker for the Identification of Multidrug Resistance Associated with Ethambutol in Mycobacterium tuberculosis, Antimicrobial Agents and Chemotherapy, 59: 5455- 5462.

Dewi R, Ahmad W. 2019. Mengenal Tuberculosis. CV. Pena Persada. https://thesiscommons.org/h9asb/download

Dubei, et al. 2012. Antimicrobials of plant origin against TB and other infections and Economics of plant drugs –Introspection

Falzon, D., et al. 2011. WHO Guidelines for The Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. European Respiratory Journal. 38(3):516-528.

Fox, H.H., 1952, The Chemical Approach to The Control of Tuberculosis, *Science*, **116**, 129– 134.

H. M. El Sahly, R. A. Reich, S. J. Dou, J. M. Musser, and E. A. Graviss, “The effect of mannose binding lectin gene polymor- phisms on susceptibility to tuberculosis in different ethnic groups,” Scandinavian Journal of Infectious Diseases, vol. 36, no. 2, pp. 106–108, 2004.

H. M. El Sahly, R. A. Reich, S. J. Dou, J. M. Musser, and E. A. Graviss, “The effect of mannose binding lectin gene polymor- phisms on susceptibility to tuberculosis in different ethnic groups,” Scandinavian Journal of Infectious Diseases, vol. 36, no. 2, pp. 106–108, 2004.

Hazbón, M.H., Brimacombe, M., Bobadilla del Valle, M., Cavatore, M., Guerrero, M.I., Varma-Basil, M., Billman-Jacobe, H., Lavender, C., Fyfe, J., García-García, L., dkk., 2006, Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant *Mycobacterium tuberculosis*, *Antimicrob. Agents Chemother.*, **50**, 2640–2649.

Hoagland, D.T., Liu, J., Lee, R.B. & Lee., R.E., 2016, New Agents for the Treatment of Drug- Resistant *Mycobacterium tuberculosis*, *Advanced Drug Delivery Reviews*, **102**, 55–72. https://tbindonesia.or.id/wp-content/uploads/2021/06/INDONESIA-JEMM-2020-Eng-1.pdf

Jagielski T, Bakuła Z, Roeske K, Kamiński M, Napiórkowska A, Augustynowicz-Kopeć E, Zwolska Z, Bielecki J. Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2014 Sep;69(9):2369-75. doi: 10.1093/jac/dku161. Epub 2014 May 22. PMID: 24855126.

Janan M. Faktor-faktor Risiko yang Berhubungan dengan Peningkatan Prevalensi Kejadian TB MDR di Kabupaten Brebes Tahun 2011-2017. J Kebijak Kesehat Indones JKKI. 2019;8(2):64–70

Johnson, R., Streicher, E.M., Gail E., Louw, Robin, M., Warren, Paul, D., Thomas, C. & Victor, 2005, Drug Resistance in *Mycobacterium tuberculosis, Curr. Issues Mol. Biol*, **8**, 97–112.

Kakimoto, S., Tone, I., 1965, Antituberculous Compounds, *J Med Chem*, **8**, 868.

Kementerian Kesehatan RI.Tuberculosis: Temukan Obati Sampai Sembuh. Jakarta: infodatin. Kementrian Kesehatan RI; 2016.

Li, Y., Wang, Y., Zhang, Z., Gao, H., Wang, H., Cao, J., Zhang, S., Liu, Y., Lu, J., Xu, Z., and Daia, E., 2016. Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles, and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China, Antimicrobial Agents and Chemotheramy, 60: 7295-7301.

Liu, Yi et al. “Characterization of Mycobacterium tuberculosis strains in Beijing, China: drug susceptibility phenotypes and Beijing genotype family transmission.” *BMC infectious diseases* vol. 18,1 658. 14 Dec. 2018, doi:10.1186/s12879-018-3578-7

Ma, Z., Ginsberg, A.M. & Spigelman, 2007, *Antimycobacterium Agents*, Global Alliance for TB Drug Development, New York, USA.

Marriner, G.A., Nayyar, A., Eugene, U., Sharon, Y., Wong, Mukherjee, T., Laura, E., Via, M.C., Rachel, L. E.,Todd, D., Gruber, Choi, I., Lee, J., Arora, K., Kathleen, D. E., Helena I.M., Clifton, E. & Barry, 2011,

The Medicinal Chemistry of Tuberculosis Chemotherapy, *Top Med Chem,* **7**, 47–124.

Nugrahaeni DK, Malik US. Analisis Penyebab Resistensi Obat Anti Tuberkulosis. J Kesehat Masy. 2013;8(2):113–20.

Pelletier, H. & Kraut, J., 1992, Crystal Structure of a Complex Between Electron Transfer Partners, Cytochrome C Peroxidase and Cytochrome C, **258**, 1748– 1755.

Ramaswamy, S., dkk., 2000, Molecular Genetic Analysis of Nucleotide Polymorphisms Associated with Ethambutol Resistance in Human Isolates of *Mycobacterium tuberculosis*, *Antimicrob Agents Chemother,* **44**, 326-336.

Rattan, A., Kalia, A., and Ahmad, N. (1998). Multidrug-Resistant Mycobacterial tuberculosis : Molecular Perspective. Emerging Infectious Disease. Halaman 195- 206.

Rouse, D.A., DeVito J.A., Li, Z., Byer, H., Morris, S.L., 1996, Site-Directed Mutagenesis of the *katG* gene of *Mycobacterium tuberculosis:*Effects on Catalase-Peroxidase Activities and Isoniazid Resistance, *Mol. Microbiol*, **22**, 583–592.

Rozwarski, D.A., Grant, G.A., Barton, D.H., Jacobs, W.R., Sacchettini, J.C., 1998, Modification of the NADH of the Isoniazid Target (InhA) from *Mycobacterium tuberculosis*, *Science,* **279**, 98–102.

Rubbo, S.D., Edgar, J. & Vaughan, G., 1957, Chemotherapy of Tuberculosis, Antituberculous Activity of Verazide and Related Hydrazones, *Am Rev Tuberc*, **76**, 331–345.

Rubbo, S.D., Rouch, L.C., Egan, J.B., Waddington, A.L. & Tellesson ,W.G., 1958, Chemotherapy of Tuberculosis, III. Verazide in the Treatment of Pulmonary Tuberculosis. *Am Rev Tuberc,* **78**, 251–258.

Slayden, R.A. & Barry, C.E., III, 2000, The Genetics and Biochemistry of Isoniazid Resistance in *Mycobacterium tuberculosis*, *Microbes. Infect*., **2**, 659–669.

Sola,C., Filliol, I., Gutierrez, MC., Mokrousov, I., Vincent, V., Rastogi, N. Spoligotype Database of Mycobacterium tuberculosis: Biogeographic Distribution of Shared Types and Epidemiologic and Phylogenetic Perspectives. Emerging Infectious Disease Journal 2001 : 7: 390-396

Sudjadi. 2008. Bioteknologi Kesehatan. Penerbit Kanisius. Yogyakarta.

Takayama, K. & Kilburn, J.O., 1989, Inhibition of Synthesis of Arabinogalactan by Ethambutol in *Mycobacterium smegmatis*, *Antimicrob. Agents Chemother*, 33, 1493–1499.

The Republic of Indonesia Joint External Monitoring Mission for Tuberculosis. 2020. Tombokan GA. Gambaran faktor risiko pengobatan tuberkulosis paru di kota Manado tahun 2014. J kedokt komunitas dan tropik. 2015;3(4):249-58

Turner RD, Bothamley GH. Cough and the transmission of tuberculosis. J Infect Dis 2015; 211:1367–72

Vilchèze, C., Jacobs, W.R., 2007, The Mechanism of Isoniazid Killing: Clarity Through the Scope of Genetics, *Annu. Rev. Microbiol*, **61**, 35–50.

Winder, F.G., Collins, P.B. & Whelan, D., 1971, Effects of Ethionamide and Isoxyl on Mycolic Acid Synthesis in *Mycobacterium tuberculosis* BCG, *J Gen Microbiol,* **66**, 379–380.

World Health Organization, 2011, Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource Constrained

World Health Organization. Global tuberculosis report 2018 . Geneva : WHO , 2018. www.who.int/tb/publications/global_report/en/ [Accessed 19 June] .

World Health Organization. Global tuberculosis report 2020. Geneva, Switzerland: World Health Organization; 2020. https://www.who.int/ teams/global-tuberculosis- programme/tb-reports

Y. H. Lee and G. G. Song, “Vitamin D receptor gene FokI, TaqI, BsmI, and ApaI polymorphisms and susceptibility to pulmonary tuberculosis: a meta-analysis,” Genetics and Molecular Research, vol. 14, no. 3, pp. 9118–9129, 2015.

Zhang, H., Chen, X., Wang, Z., Ren, Z., Wu, J., Sun, H. and Bai, X., 2015.40 Cakra Kimia (Indonesian E-Journal of Applied Chemistry) ISSN 2302-7274 Volume 8, Nomor 1, Mei 2020 49 Pyrosequencing analysis for mutations in embB codon306 among clinical Mycobacterium tuberculosis isolates from Qingdao, China. Int J Clin Exp Med. 8 : 11276-11282

Zumla, A., Nahid, P. & Cole, S.T., 2013, Advances in the Development of New Tuberculosis Drugs And Treatment Regimens, *Nat. Rev. Drug Discov*., **12**, 388-404

LAMPIRAN

Lampiran 1. Hasil Amplifikasi Gen katG, inhA, dan ahpC








M
K-
K+
60
61
62
63
64
65
66
67
68
69
70
71
72
73
383 bp
296 bp
193 bp


M
K-
K+
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
383 bp
296 bp
193 bp


M
K-
K+
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
383 bp
296 bp
193 bp


M
K-
K+
106
107
108
109
110
111
112
113
114
115
116
117
118
119
383 bp
296 bp
193 bp


M
K-
K+
120
121
122
123
124
125
126
127
128
129
130
131
132


M
K-
K+
133
134
135
136
137
138
139
140
141


M K- K+ 142143144 145 146 147
383 bp
296 bp
193 bp


M K- K+148 149150 151152 153 154 155 156
383 bp
296 bp
193 bp


M K- K+ 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172
383 bp
296 bp
193 bp


M K- K+ 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189
383 bp
296 bp
193 bp


M K- K+ 190 191 192 193 194 195 196 197 198 199 200 36 40 42 43 51 53
383 bp
296 bp
193 bp


M K- K+ 54 66 78 80 99 106 110 125 139 155 156 170 178 187 195 196 199
383 bp
296 bp
193 bp

Lampiran 2. Dokumentasi Penelitian




LABCULTURE


LIGHT UP YOUR DAY
LABCULTURE

Lampiran 3. Primer terhadap Genom M. tuberkulosis H37Rv

GENOM INHA

TTATGTAGCGCGACATACCTGCTGCGCAATTCGTAGGGCGTCAATACACCCGCAGCCAGGGCCTCGCT
GC
CCAGAAAGGGATCCGTCATGGTCGAAGTGTGCTGAGTCACACCGACAAACGTCACGAGCGTAACCCCA
GT
GCGAAAGTTCCCGCCGGAAATCGCAGCCACGTTACGCTCGTGGACATACCGATTTCGGCCCGGCCGCG
GC
GAGACGATAGGTTGTCGGGGTGACTGCCACAGCCACTGAAGGGGCCAAACCCCCATTCGTATCCCGTT
CA
GTCCTGGTTACCGGAGGAAACCGGGGGATCGGGCTGGCGATCGCACAGCGGCTGGCTGCCGACGGCCA
CA
AGGTGGCCGTCACCCACCGTGGATCCGGAGCGCCAAAGGGGCTGTTTGGCGTCGAATGTGACGTCACC
GA
CAGCGACGCCGTCGATCGCGCCTTCACGGCGGTAGAAGAGCACCAGGGTCCGGTCGAGGTGCTGGTGT
CC
AACGCCGGCCTATCCGCGGACGCATTCCTCATGCGGATGACCGAGGAAAAGTTCGAGAAGGTCATCAA
CG
CCAACCTCACCGGGGCGTTCCGGGTGGCTCAACGGGCATCGCGCAGCATGCAGCGCAACAAATTCGGT
CG
AATGATATTCATAGGTTCGGTCTCCGGCAGCTGGGGCATCGGCAACCAGGCCAACTACGCAGCCTCCA
AG
GCCGGAGTGATTGGCATGGCCCGCTCGATCGCCCGCGAGCTGTCGAAGGCAAACGTGACCGCGAATGT
GG
TGGCCCCGGGCTACATCGACACCGATATGACCCGCGCGCTGGATGAGCGGATTCAGCAGGGGGCGCTG
CA
ATTTATCCCAGCGAAGCGGGTCGGCACCCCCGCCGAGGTCGCCGGGGTGGTCAGCTTCCTGGCTTCCG
AG
GATGCGAGCTATATCTCCGGTGCGGTCATCCCGGTCGACGGCGGCATGGGTATGGGCCACTGACACAA
CA
CAAGGACGCACATGACAGGACTGCTGGACGGCAAACGGATTCTGGTTAGCGGAATCATCACCGACTCG
TC
GATCGCGTTTCACATCGCACGGGTAGCCCAGGAGCAGGGCGCCCAGCTGGTGCTCACCGGGTTCGACC
GG
CTGCGGCTGATTCAGCGCATCACCGACCGGCTGCCGGCAAAGGCCCCGCTGCTCGAACTCGACGTGCA
AA
ACGAGGAGCACCTGGCCAGCTTGGCCGGCCGGGTGACCGAGGCGATCGGGGCGGGCAACAAGCTCGAC
GG
GGTGGTGCATTCGATTGGGTTCATGCCGCAGACCGGGATGGGCATCAACCCGTTCTTCGACGCGCCCT
AC
GCGGATGTGTCCAAGGGCATCCACATCTCGGCGTATTCGTATGCTTCGATGGCCAAGGCGCTGCTGCC
GA
TCATGAACCCCGGAGGTTCCATCGTCGGCATGGACTTCGACCCGAGCCGGGCG`ATGCCGGCCTACAA
CT
GGATGACGGTCGCCAAGAGCGCGTTGGAGTCGGTCAACAGGTTCGTGGCGCGCGAGGCCGGCAAGTAC
GGT

CGATAGGTTGTCGGGGTG: FORWARD COMPLEMENT PRIMER
GTCAATACACCCGCAGCCAG: REVERSE PRIMER
NC_000962.3 (1674202..1675011): POSISI

GENOM KATG

GTGCCCGAGCAACACCCACCCATTACAGAAACCACCACCGGAGCCGCTAGCAACGGCTGTCCCGTCGT
GG
GTCATATGAAATACCCCGTCGAGGGCGGCGGAAACCAGGACTGGTGGCCCAACCGGCTCAATCTGAAG
GT
ACTGCACCAAAACCCGGCCGTCGCTGACCCGATGGGTGCGGCGTTCGACTATGCCGCGGAGGTCGCGA
CC
ATCGACGTTGACGCCCTGACGCGGGACATCGAGGAAGTGATGACCACCTCGCAGCCGTGGTGGCCCGC
CG
ACTACGGCCACTACGGGCCGCTGTTTATCCGGATGGCGTGGCACGCTGCCGGCACCTACCGCATCCAC
GA
CGGCCGCGGCGGCGCCGGGGGCGGCATGCAGCGGTTCGCGCCGCTTAACAGCTGGCCCGACAACGCCA
GC
TTGGACAAGGCGCGCCGGCTGCTGTGGCCGGTCAAGAAGAAGTACGGCAAGAAGCTCTCATGGGCGGA
CC
TGATTGTTTTCGCCGGCAACTGCGCGCTGGAATCGATGGGCTTCAAGACGTTCGGGTTCGGCTTCGGC
CG
GGTCGACCAGTGGGAGCCCGATGAGGTCTATTGGGGCAAGGAAGCCACCTGGCTCGGCGATGAGCGTT
AC
AGCGGTAAGCGGGATCTGGAGAACCCGCTGGCCGCGGTGCAGATGGGGCTGATCTACGTGAACCCGGA
GG
GGCCGAACGGCAACCCGGACCCCATGGCCGCGGCGGTCGACATTCGCGAGACGTTTCGGCGCATGGCC
AT
GAACGACGTCGAAACAGCGGCGCTGATCGTCGGCGGTCACACTTTCGGTAAGACCCATGGCGCCGGCC
CG
GCCGATCTGGTCGGCCCCGAACCCGAGGCTGCTCCGCTGGAGCAGATGGGCTTGGGCTGGAAGAGCTC
GT
ATGGCACCGGAACCGGTAAGGACGCGATCACCAGCGGCATCGAGGTCGTATGGACGAACACCCCGACG
AA
ATGGGACAACAGTTTCCTCGAGATCCTGTACGGCTACGAGTGGGAGCTGACGAAGAGCCCTGCTGGCG
CT
TGGCAATACACCGCCAAGGACGGCGCCGGTGCCGGCACCATCCCGGACCCGTTCGGCGGGCCAGGGCG
CT
CCCCGACGATGCTGGCCACTGACCTCTCGCTGCGGGTGGATCCGATCTATGAGCGGATCACGCGTCGC
TG
GCTGGAACACCCCGAGGAATTGGCCGACGAGTTCGCCAAGGCCTGGTACAAGCTGATCCACCGAGACA
TG
GGTCCCGTTGCGAGATACCTTGGGCCGCTGGTCCCCAAGCAGACCCTGCTGTGGCAGGATCCGGTCCC
TG
CGGTCAGCCACGACCTCGTCGGCGAAGCCGAGATTGCCAGCCTTAAGAGCCAGATCCGGGCATCGGGA
TT
GACTGTCTCACAGCTAGTTTCGACCGCATGGGCGGCGGCGTCGTCGTTCCGTGGTAGCGACAAGCGCG
GC
GGCGCCAACGGTGGTCGCATCCGCCTGCAGCCACAAGTCGGGTGGGAGGTCAACGACCCCGACGGGGA
TC
TGCGCAAGGTCATTCGCACCCTGGAAGAGATCCAGGAGTCATTCAACTCCGCGGCGCCGGGGAACATC
AA
AGTGTCCTTCGCCGACCTCGTCGTGCTCGGTGGCTGTGCCGCCATAGAGAAAGCAGCAAAGGCGGCTG
GC
CACAACATCACGGTGCCCTTCACCCCGGGCCGCACGGATGCGTCGCAGGAACAAACCGACGTGGAATC
CT

TTGCCGTGCTGGAGCCCAAGGCAGATGGCTTCCGAAACTACCTCGGAAAGGGCAACCCGTTGCCGGCC
GA
GTACATGCTGCTCGACAAGGCGAACCTGCTTACGCTCAGTGCCCCTGAGATGACGGTGCTGGTAGGTG
GC
CTGCGCGTCCTCGGCGCAAACTACAAGCGCTTACCGCTGGGCGTGTTCACCGAGGCCTCCGAGTCACT
GA
CCAACGACTTCTTCGTGAACCTGCTCGACATGGGTATCACCTGGGAGCCCTCGCCAGCAGATGACGGG
AC
CTACCAGGGCAAGGATGGCAGTGGCAAGGTGAAGTGGACCGGCAGCCGCGTGGACCTGGTCTTCGGGT
CC
AACTCGGAGTTGCGGGCGCTTGTCGAGGTCTATGGCGCCGATGACGCGCAGCCGAAGTTCGTGCAGGA
CT
TCGTCGCTGCCTGGGACAAGGTGATGAACCTCGACAGGTTCGACGTGCGCTGA

CAGATGGGGCTGATCTACG: FORWARD PRIMER
GCGGCATCGAGGTCGTATGG: REVERSE COMPLEMENT PRIMER
NC_000962.3 (2153889..2156111, complement: POSISI

GENOM AHPC

CTGAACCACTGCTTTGCCGCCACCGCGGCGAACGCGCGAAGCCCGGCCACGGCCGGCTAGCACCTCTT
GG
CGGCGATGCCGATAAATATGGTGTGATATATCACCTTTGCCTGACAGCGACTTCACGGCACGATGGAA
TG
TCGCAACCAAATGCATTGTCCGCTTTGATGATGAGGAGAGTCATGCCACTGCTAACCATTGGCGATCA
AT
TCCCCGCCTACCAGCTCACCGCTCTCATCGGCGGTGACCTGTCCAAGGTCGACGCCAAGCAGCCCGGC
GA
CTACTTCACCACTATCACCAGTGACGAACACCCAGGCAAGTGGCGGGTGGTGTTCTTTTGGCCGAAAG
AC
TTCACGTTCGTGTGCCCTACCGAGATCGCGGCGTTCAGCAAGCTCAATGACGAGTTCGAGGACCGCGA
CG
CCCAGATCCTGGGGGGTTTCGATTGACAGCGAATTCGCGCATTTCCAGTGGCGTGCACAGCACAACGAC
CT
CAAAACGTTACCCTTCCCGATGCTCTCCGACATCAAGCGCGAACTCAGCCAAGCCGCAGGTGTCCTCA
AC
GCCGACGGTGTGGCCGACCGCGTGACCTTTATCGTCGACCCCAACAACGAGATCCAGTTCGTCTCGGC
CA
CCGCCGGTTCGGTGGGACGCAACGTCGATGAGGTACTGCGAGTGCTCGACGCCCTCCAGTCCGACGAG
CT
GTGCGCATGCAACTGGCGCAAGGGCGACCCGACGCTAGACGCTGGCGAACTCCTCAAGGCTTCGGCCT
AA
CCGGGATCTGGTTGGCCGGGAATCAATGAGTATAGAAAAGCTCAAGGCCGCGCTCCCCGAGTACGCCA
AA
GACATCAAGCTGAACCTGAGCTCAATCACCCGCAGCAGCGTGCTCGACCAGGAACAACTATGGGGAAC
CC

ATGCCGATAAATATGGTGTG: FORWARD PRIMER
TCGATTGACAGCGAATTCGC: REVERSE COMPLEMENT PRIMER
NC_000962.3 (2726193..2726780: POSISI